trending Market Intelligence /marketintelligence/en/news-insights/trending/O1Y1-ZrMTf8xLmBMFiZQlQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi's dengue vaccine Dengvaxia approved for use in Europe

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sanofi's dengue vaccine Dengvaxia approved for use in Europe

Sanofi's dengue vaccine Dengvaxia has been approved by the European Commission to prevent the virus infection in individuals who have previously been infected.

The French pharmaceutical giant, which spent two decades developing the world's first dengue vaccine, said Dengvaxia is used to prevent dengue fever in people aged nine to 45 years.

The approval follows the decision of the European Medicines Agency, which recommended the use of the vaccine to prevent fever caused by dengue virus serotypes 1, 2, 3 and 4 in the EU.

Dengue fever is a mosquito-borne infection that people can get up to four times in a lifetime. The disease is endemic in several European territories located in tropical and subtropical climates prone to outbreaks, especially during the rainy season.

Dengvaxia came under scrutiny in 2017 when Sanofi said the vaccine should not be recommended for people who have not previously been infected by the virus, as severe cases of the disease can occur in these people who contract dengue after vaccination. Sanofi, however, stood by the medicine and said it offered "strong and persistent" protection in people aged nine and above. An advisory panel of the World Health Organization also backed the use of Dengvaxia but only after individuals have been tested for previous exposure to the virus.

Sanofi said in a Dec. 19 press release that the vaccine has been evaluated in studies involving more than 40,000 people from 15 countries with up to six years of follow-up data on safety and efficacy.

Sanofi is also developing a diagnostic test, which is expected to be ready in the second half of 2020, to facilitate broader use of the dengue vaccine. Dengvaxia is under priority review by the U.S. Food and Drug Administration and a decision is expected by May 1, 2019.